ClinicalTrials.gg
Not yet recruitingNCT07389187Updated Nov 18, 2026

Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

An Early Phase 1 interventional study of LC-K76 and Tislelizumab in mCRPC, sponsored by Shanghai Changzheng Hospital. Not yet recruiting at 1 site in China. Open to male participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Shanghai Changzheng Hospital · Early Phase 1, Interventional, and Treatment

How we know

Updated Nov 18, 2026Start date movedPrimary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
Male
01

Study summary

This open-label, single-arm study evaluates the safety and preliminary efficacy of LC-K76 combined with Tislelizumab and ADT in 10 patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) who progressed on prior therapies. Participants will receive oral LC-K76 and intravenous Tislelizumab for a 24-week treatment period.

02

Conditions studied

  • mCRPC
03

In context

Lead sponsor

Shanghai Changzheng Hospital is the lead sponsor of 128 studies on the registry; 60 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male, aged 18 to 85 years.
  2. confirmed prostate adenocarcinoma, without small cell carcinoma components.
  3. Castration-Resistant Prostate Cancer (mCRPC) with disease progression after at least one novel endocrine therapy (e.g., abiraterone or enzalutamide) and/or docetaxel chemotherapy.
  4. Evidence of bone metastasis on PSMA-PET-CT or bone scan (ECT).
  5. Serum testosterone at castration levels (\< 50 ng/dL or 1.75 nmol/L).
  6. performance status ≤ 2.
  7. > 6 months.
  8. Adequate bone marrow, hepatic, and renal function.
  9. Willing to undergo before and during treatment

Exclusion criteria

Exclusion Criteria:

  1. Lack of pathological evidence for prostate cancer.
  2. Other primary malignant tumors active or requiring treatment within the past 3 years.
  3. Has visceral .
  4. Poorly controlled diabetes after continuous insulin therapy.
  5. Significant abnormalities in laboratory values at randomization ( \< 90 g/L; Neutrophils \< 1.5x10\^9/L; \< 75x10\^9/L; /AST > 2.5xULN; > 1.5xULN; \< 60 mL/min/1.73m\^2) .
  6. Severe cardiopulmonary disease or high-risk conditions.
  7. Prior therapy with any (e.g., anti-PD-1/PD-L1).
  8. Intolerance to anti-PD-1 monoclonal antibody or dandelion extracts.
  9. History of severe drug allergies.
  10. Factors affecting drug intake/absorption (e.g., swallowing difficulty, chronic diarrhea).
  11. Concurrent psychiatric or neurological conditions
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    LC-K76 + Tislelizumab + ADT

    Participants receive oral LC-K76 combined with intravenous Anti-PD-1 monoclonal antibody (Tislelizumab) and standard androgen deprivation therapy (ADT). Treatment continues for 24 weeks.

    Dietary Supplement: LC-K76 · Drug: Tislelizumab · Drug: Standard Androgen Deprivation Therapy (ADT)

Interventions

  • Dietary supplementLC-K76

    Oral administration, 1.2 g twice daily (BID), taken 30 minutes before breakfast and dinner.

  • Intravenous infusion, 200 mg every 3 weeks (Q3W).

  • DrugStandard Androgen Deprivation Therapy (ADT)

    Maintenance of ADT using GnRH agonist or antagonist (e.g., Goserelin, Leuprorelin, Triptorelin, or Degarelix).

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events (AEs)

    The Incidence of Adverse Events is defined as the proportion of subjects in a clinical trial who experience at least one Adverse Event (AE) during the defined observation period, which is assessed by CTCAE 5.0.

    Time frame: From baseline to primary completion, which may take up to 24 to 48 weeks

Secondary outcomes

  1. PSA Response Rate

    Time frame: From baseline to primary completion, which may take up to 24 to 48 weeks

  2. Disease control rate (DCR)

    Defined as the proportion of subjects whose best overall response, assessed per RECIST 1.1 and PCWG3, is Complete Response (CR), Partial Response (PR), or Stable Disease (SD) .

    Time frame: From baseline to primary completion, which may take up to 24 to 48 weeks

  3. Radiographic Progression-Free Survival (rPFS)

    Defined as the time from treatment initiation to the first objective evidence of disease progression as assessed by radiographic imaging, or death from any cause, whichever occurs first.

    Time frame: From baseline to primary completion, which may take up to 24 to 48 weeks

  4. Time to First Skeletal-Related Event (SRE)

    Defined as the interval from the date of treatment initiation to the date of the first occurrence of any of the following clinically significant events attributable to bone metastasis: pathological fracture (vertebral or non-vertebral), palliative radiation therapy to bone for pain relief, surgical intervention to bone to prevent or treat a fracture or spinal cord compression, or confirmed spinal cord compression.

    Time frame: From baseline to primary completion, which may take up to 24 to 48 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Jun 2027; primary completion for Dec 2027, 6 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: start Feb 2026 → Jun 2027 and primary completion Dec 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 28, 2025
First posted
Feb 5, 2026
StartEst.
Jun 2027was Feb 2026
Primary completionEst.
Dec 2027was Dec 2026
CompletionEst.
Jun 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Feb 2026→Jun 2027
Nov 18, 2026
Primary completion
Dec 2026→Dec 2027
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Start date Feb 2026→Jun 2027
    Primary completion Dec 2026→Dec 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07389187
Responsible party
Ren Shancheng (Professor, Chief of Urology, Shanghai Changzheng Hospital) — Principal investigator
First posted
Feb 5, 2026
Start date
Jun 2027 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Jun 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Ren, MD,PhD
Contact
renshancheng@gmail.com
86021-81886999

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion